192185-51-6

Basic information

• Product Name: 2(1H)-Quinolinone, 4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl )methyl]-1-methyl-
• CAS NO: 192185-51-6
• Molecular Formula: C27H21Cl2N3O2
• Molecular Weight: 490.389
• Mol File: 192185-51-6.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2(1H)-Quinolinone, 4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl )methyl]-1-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 2(1H)-Quinolinone, 4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl )methyl]-1-methyl-(192185-51-6)
• EPA Substance Registry System: 2(1H)-Quinolinone, 4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl )methyl]-1-methyl-(192185-51-6)

Safety Data

• Hazardous Substances Data: 192185-51-6(Hazardous Substances Data)

Upstream product

• 192185-71-0 tiparfinib 
• 192185-72-1 tipifarnib 
• 405548-67-6 N-[2-(3-chlorobenzoyl)-4-(4-chlorobenzoyl)phenyl]acetamide 
• 192187-32-9 R₁₀₁₇₆₃ 
• 406162-21-8 (4-chlorophenyl)-[4-(3-chlorophenyl)-2-methoxyquinolin-6-yl]methanone 
• 190898-77-2 3-(3-chlorophenyl)-5-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-2,1-benzisoxazole 
• 190898-78-3 [2-amino-5-(4-chlorobenzoyl)phenyl](3-chlorophenyl)-methanone 
• 190898-64-7 2-(4-Chlorophenyl)-2-(4-nitrophenyl)-1,3-dioxolane 
• 74-11-3 para-chlorobenzoic acid 
• 65247-25-8 (2-amino-5-bromo-phenyl)-(3-chloro-phenyl)-methanone 
• 7497-60-1 (4-Chlorophenyl)(4-nitrophenyl)methanone 
• 1529-41-5 3-chloro-benzeneacetonitrile 
• 616-47-7 1-methyl-1H-imidazole 
• 192187-33-0 R₁₀₄₂₀₉ 

Downstream Products

• 192185-68-5 6-[amino(4-chlorophenyl)-1-methyl-1H-imidazol-5-ylmethyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone 
• 192185-72-1 tipifarnib 

Relevant articles and documents

Development of a Recycling Process for an Industrial-Scale Production of Tipifarnib

Current production of tipifarnib involves a late-stage chiral resolution where the mother liquor containing ～2/3 of the product is disposed of as waste. As part of an effort to develop an efficient recycling process, a NaNO2-mediated racemization was initially devised and successfully implemented at kilogram scale. However, formation of a new hard-to-purge impurity and concerns about potential N-nitrosamine contamination prompted exploration of a NaNO2-free process. Additional experimentation with acidic conditions at elevated temperatures afforded a highly efficient, robust recycling process that was seamlessly incorporated into the original process. The resulting production output of tipifarnib increased over 60%, and waste disposal was dramatically decreased.

Farnesyl Protein transferase inhibitors with in vivo radiosensitizing properties

The present invention is concerned with the finding that farnesyl protein transferase inhibitors have radiosensitizing properties which makes them useful for preparing a pharmaceutical composition for administration before, during or after irradiation of a tumor for treating cancer in vivo.

Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quionlinone derivatives

PCT No. PCT/EP96/04515 Sec. 371 Date May 26, 1998 Sec. 102(e) Date May 26, 1998 PCT Filed Oct. 16, 1996 PCT Pub. No. WO97/21701 PCT Pub. Date Jun. 19, 1997This invention comprises the novel compounds of formula (I) wherein the dotted line represents an op